Joint British Society for Haematology/American Society of Hematology Session
Monday 16 April: 09:15 – 10:30
Presenter: Dr Peter Campbell
Presentation title - The transformative impact of genomics in management of haematological malignancies
Dr Peter Campbell, Head of Cancer, Ageing and Somatic Mutation, and Senior Group Leader, Wellcome Trust Sanger Institute
Dr Peter Campbell is Head of Cancer Genetics and Genomics at the Wellcome Trust Sanger Institute, having started a Wellcome Trust Senior Clinical Fellowship in 2010. He completed specialist training in Haematology in 2002. Following this, he completed a PhD at the University of Cambridge in the molecular pathogenesis and clinical management of myeloproliferative disorders. Since 2007, Dr Campbell has been employed at the Cancer Genome Project, Wellcome Trust Sanger Institute. In 2010, he was awarded the CR-UK Future Leaders in Cancer Research Prize.
The Dacie/Wilkinson Lecture
Tuesday 17 April: 11:45 - 12:30
Presenter: Professor Bob Löwenberg
Bob Löwenberg, Professor of Hematology, Erasmus University Medical School
Bob Löwenberg’s research is concerned with developmental diagnostics and therapeutics, in particular in acute myeloid leukemia (AML) in the context of single center and multicenter prospective clinical trials. These trials evaluate novel agents and novel therapeutic approaches with account of the molecular heterogeneity of the disease. The large phase II and phase II studies are embedded in the HOVON Cooperative Group Network. Other activities relate to the in depth genomic analysis of banked AML patient specimens, eg with regard to their therapeutic impact and prognostic significance. Research is conducted in close cooperation with various other colleague investigators at the Dept of Hematology at the ErasmusMC Rotterdam.
BSH Medal Lecture
Wednesday 18 April: 12:30 - 13:15
Presenter: Professor John Porter
John Porter, Professor of Haematology and Consultant Haematologist, University College London Hospitals
John Porter is Professor of Haematology and Consultant Haematologist at the University College London Hospitals in London, UK and head of the joint Red Cell Unit for UCLH and Whittington Hospitals. He graduated from the University of Cambridge in 1974 was awarded an FRCP by the Royal London College of Physicians in 1995 and FRCPath in Haematology by the Royal College of Pathologists in 1996.
His clinical and research focus has been treatments of thalassaemia and sickle cell disorders, with particular reference to iron overload, the mechanisms of iron chelation, the speciation and uptake of non-transferrin-bound iron (NTBI) species, the molecular basis of iron homeostasis in health and disease, and the actions and toxicities of mixed-ligand chelation therapies. He has received funding from many sources including the Medical Research Council (MRC), the Welcome Foundation and National Institutes of Health (NIH) for this work. Professor Porter has been the principal UK investigator in numerous multicentre clinical trials on iron chelation and is currently the principal UK investigator on ongoing trials with Luspatercept for correcting anaemia in Thlassaemias (Celgene) and Gene therapy for Thalassaemia (Bluebird Bio).
Professor Porter has published more than 350 peer-reviewed articles with over 10,000 citations and an H index of 52. He has also made numerous contributions to books, as well as clinical guidelines and other medical articles. He has served as scientific adviser to the British Society of Haematology, the UK Thalassaemia Society, the Thalassaemia International Federation (TIF), and to grant review and advisory panels at the NIH in Bethesda, MD, USA. In 1999 he was awarded the Lionel Whitby Medal for MD of exceptional merit by Cambridge University. In 2008 he received the Prix Gallien at the houses of parliament on behalf of Novartis for 'Deferasirox as outstanding orphan drug'. In 2015 he received the SITA international award for outstanding international clinical thalassaemia centre at UCLH. In 2017 he received the IBIS Marcel Simon award from the International BioIron society for excellence in research on Non-transferrin bound iron (NTBI). He is the recent recipient of the British Society of Haematology Gold Medal award.